comparemela.com

CANbridge Announces Marketing Approval of CAN108 (/LIVMARLI®) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (ALGS)

CANbridge Announces Marketing Approval of CAN108 (/LIVMARLI®) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (ALGS)

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States ,Canada ,Taiwan ,China ,Hong Kong ,Burlington ,Newfoundland ,Beijing ,Hepatol Comms ,Pediatr Gastroenterol Nutr ,James Xue ,Clin Genet ,Source Canbridge Pharmaceuticals Inc ,Drug Administration ,Canbridge Pharmaceuticals Inc ,National Rare Diseases Registry System ,Second National List Of Rare Diseases ,Mirum Pharmaceuticals Inc ,Development Facility ,Prnewswire Canbridge Pharmaceuticals Inc ,Only Treatment Approved ,Cholestatic Pruritus ,Mainland China ,Maralixibat Chloride Oral Solution ,Taiwan Food ,Mirum Pharmaceutical ,Mirum Pharmaceuticals ,Global Phase ,Breakthrough Therapy ,Alagille Syndrome ,National List ,Fat Soluble Vitamin ,Process Development Facility ,Pharmaceuticals Inc ,

comparemela.com © 2020. All Rights Reserved.